Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Nuclear transport of cancer extracellular vesicle-derived biomaterials through nuclear envelope invagination-associated late endosomes.

Rappa G, Santos MF, Green TM, Karbanov√° J, Hassler J, Bai Y, Barsky SH, Corbeil D, Lorico A.

Oncotarget. 2017 Feb 28;8(9):14443-14461. doi: 10.18632/oncotarget.14804.

2.

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype.

Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A.

Biomed Res Int. 2015;2015:634865. doi: 10.1155/2015/634865. Epub 2015 Oct 27. Review.

3.

The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.

Robertson FM, Chu K, Boley KM, Ye Z, Liu H, Wright MC, Moraes R, Zhang X, Green TL, Barsky SH, Heise C, Cristofanilli M.

J Exp Ther Oncol. 2013;10(3):219-33.

PMID:
24416998
4.

Presence of anaplastic lymphoma kinase in inflammatory breast cancer.

Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M.

Springerplus. 2013 Oct 1;2:497. doi: 10.1186/2193-1801-2-497. eCollection 2013.

5.

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Waldron NN, Barsky SH, Dougherty PR, Vallera DA.

Target Oncol. 2014 Sep;9(3):239-49. doi: 10.1007/s11523-013-0290-9. Epub 2013 Jul 31.

6.
7.

Early to intermediate steps of tumor embolic formation involve specific proteolytic processing of E-cadherin regulated by Rab7.

Ye Y, Gao JX, Tian H, Yearsley K, Lange AR, Robertson FM, Barsky SH.

Mol Cancer Res. 2012 Jun;10(6):713-26. doi: 10.1158/1541-7786.MCR-12-0009. Epub 2012 May 25.

8.

The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin.

Ye Y, Tian H, Lange AR, Yearsley K, Robertson FM, Barsky SH.

Oncogene. 2013 Mar 28;32(13):1702-13. doi: 10.1038/onc.2012.180. Epub 2012 May 14.

PMID:
22580607
10.

KIAA0101 interacts with BRCA1 and regulates centrosome number.

Kais Z, Barsky SH, Mathsyaraja H, Zha A, Ransburgh DJ, He G, Pilarski RT, Shapiro CL, Huang K, Parvin JD.

Mol Cancer Res. 2011 Aug;9(8):1091-9. doi: 10.1158/1541-7786.MCR-10-0503. Epub 2011 Jun 14.

11.

A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling.

Yokdang N, Tellez JD, Tian H, Norvell J, Barsky SH, Valencik M, Buxton IL.

Br J Cancer. 2011 May 10;104(10):1628-40. doi: 10.1038/bjc.2011.134. Epub 2011 Apr 19.

12.

Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion.

Mahooti S, Porter K, Alpaugh ML, Ye Y, Xiao Y, Jones S, Tellez JD, Barsky SH.

Oncotarget. 2010 Jun;1(2):131-47.

13.

E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.

Ye Y, Tellez JD, Durazo M, Belcher M, Yearsley K, Barsky SH.

Anticancer Res. 2010 Oct;30(10):3903-10.

PMID:
21036701
14.

Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis.

Ye Y, Yin DT, Chen L, Zhou Q, Shen R, He G, Yan Q, Tong Z, Issekutz AC, Shapiro CL, Barsky SH, Lin H, Li JJ, Gao JX.

PLoS One. 2010 Oct 20;5(10):e13406. doi: 10.1371/journal.pone.0013406.

15.

Inflammatory breast cancer: the disease, the biology, the treatment.

Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M.

CA Cancer J Clin. 2010 Nov-Dec;60(6):351-75. doi: 10.3322/caac.20082. Epub 2010 Oct 19. Review. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. Ueno, Naoto [corrected to Ueno, Naoto T].

16.

A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology.

Duke TJ, Jahed NC, Veneroso CC, Da Roza R, Johnson O, Hoffman D, Barsky SH, Levine PH.

Oncol Rep. 2010 Nov;24(5):1277-84.

PMID:
20878121
17.

The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction.

Xiao Y, Ye Y, Zou X, Jones S, Yearsley K, Shetuni B, Tellez J, Barsky SH.

Oncogene. 2011 Jan 20;30(3):287-300. doi: 10.1038/onc.2010.405. Epub 2010 Sep 13.

PMID:
20838375
18.

Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype.

Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH.

J Biomol Screen. 2010 Aug;15(7):820-9. doi: 10.1177/1087057110376541. Epub 2010 Jul 16.

PMID:
20639504
19.

A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.

Wu Y, Feng X, Jin Y, Wu Z, Hankey W, Paisie C, Li L, Liu F, Barsky SH, Zhang W, Ganju R, Zou X.

Cancer Prev Res (Phila). 2010 Jul;3(7):818-28. doi: 10.1158/1940-6207.CAPR-09-0213. Epub 2010 Jun 29.

20.

Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.

Liu JJ, Shen R, Chen L, Ye Y, He G, Hua K, Jarjoura D, Nakano T, Ramesh GK, Shapiro CL, Barsky SH, Gao JX.

Int J Clin Exp Pathol. 2010 Mar 20;3(4):328-37.

21.

Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16.

He G, Chen L, Ye Y, Xiao Y, Hua K, Jarjoura D, Nakano T, Barsky SH, Shen R, Gao JX.

Am J Transl Res. 2010 Mar 25;2(2):156-69.

22.

ERalpha signaling through slug regulates E-cadherin and EMT.

Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH.

Oncogene. 2010 Mar 11;29(10):1451-62. doi: 10.1038/onc.2009.433. Epub 2010 Jan 18.

PMID:
20101232
23.

Use and validation of epithelial recognition and fields of view algorithms on virtual slides to guide TMA construction.

Barsky S, Gentchev L, Basu A, Jimenez R, Boussaid K, Gholap A.

Biotechniques. 2009 Nov;47(5):927-38. doi: 10.2144/000113207.

24.

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS.

Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.

25.

Inhibition of expression of the chromatin remodeling gene, SNF2L, selectively leads to DNA damage, growth inhibition, and cancer cell death.

Ye Y, Xiao Y, Wang W, Wang Q, Yearsley K, Wani AA, Yan Q, Gao JX, Shetuni BS, Barsky SH.

Mol Cancer Res. 2009 Dec;7(12):1984-99. doi: 10.1158/1541-7786.MCR-09-0119. Epub 2009 Dec 8.

26.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK.

Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3.

27.

Pten in stromal fibroblasts suppresses mammary epithelial tumours.

Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC, Leone G.

Nature. 2009 Oct 22;461(7267):1084-91. doi: 10.1038/nature08486.

28.

Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.

Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA.

PLoS One. 2009;4(5):e5563. doi: 10.1371/journal.pone.0005563. Epub 2009 May 15.

29.

Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression.

Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R.

Brain Behav Immun. 2009 Feb;23(2):267-75. doi: 10.1016/j.bbi.2008.10.005. Epub 2008 Oct 21.

30.

The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.

Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH.

Am J Pathol. 2008 Aug;173(2):561-74. doi: 10.2353/ajpath.2008.071214. Epub 2008 Jul 3.

31.

ERalpha suppresses slug expression directly by transcriptional repression.

Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Barsky SH.

Biochem J. 2008 Dec 1;416(2):179-87. doi: 10.1042/BJ20080328.

32.

Precancerous stem cells can serve as tumor vasculogenic progenitors.

Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX.

PLoS One. 2008 Feb 20;3(2):e1652. doi: 10.1371/journal.pone.0001652.

33.

Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.

Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, Naik GA, Gholap AS, Barsky SH.

J Microsc. 2007 Jun;226(Pt 3):244-55.

34.

Precancerous stem cells have the potential for both benign and malignant differentiation.

Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, Yates AJ, Carson WE 3rd, Lin H, Barsky SH, Gao JX.

PLoS One. 2007 Mar 14;2(3):e293.

35.

Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer.

Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH.

Cytometry A. 2007 May;71(5):273-85.

36.

Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression.

Barsky SH, Karlin NJ.

J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):249-60. Review.

PMID:
16807804
37.

Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell.

Barsky SH, Karlin NJ.

Nat Clin Pract Oncol. 2006 Mar;3(3):138-51. Review.

PMID:
16520804
38.

Gouty panniculitis: a case report and review of the literature.

Snider AA, Barsky S.

Cutis. 2005 Jul;76(1):54-6. Review.

PMID:
16144290
39.

Novel interactions of vitamin E and estrogen in breast cancer.

Chamras H, Barsky SH, Ardashian A, Navasartian D, Heber D, Glaspy JA.

Nutr Cancer. 2005;52(1):43-8.

PMID:
16091003
40.

Anatomy of the nipple and breast ducts revisited.

Love SM, Barsky SH.

Cancer. 2004 Nov 1;101(9):1947-57.

41.

Comparison of molecular dynamics with hybrid continuum-molecular dynamics for a single tethered polymer in a solvent.

Barsky S, Delgado-Buscalioni R, Coveney PV.

J Chem Phys. 2004 Aug 1;121(5):2403-11.

PMID:
15260795
42.

Images in clinical medicine. Pseudomyxoma peritonei.

Barsky SH, McGonigle K.

N Engl J Med. 2004 Apr 8;350(15):e13. No abstract available.

43.

Angiosarcoma developing in a breast after conservation treatment for breast cancer.

Parker RG, Barsky SH, Bennion R.

Am J Clin Oncol. 2003 Oct;26(5):486-8. No abstract available.

PMID:
14528076
44.

Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.

Choi SH, Barsky SH, Chang HR.

Breast J. 2003 May-Jun;9(3):153-62.

PMID:
12752622
45.
46.

Atypical ductal hyperplasia presenting as pseudomicrocalcifications.

Tsai HC, Chang H, Barsky SH.

Breast J. 2003 Jan-Feb;9(1):39-40.

PMID:
12558669
47.

Establishment of an immortalized cell line and transplantable xenograft from a bronchioloalveolar lung carcinoma of a cat.

Grossman DA, McNiel EA, Hackett TB, Barsky SH.

Am J Vet Res. 2002 Dec;63(12):1745-53.

PMID:
12492292
48.

Cracks and crazes: on calculating the macroscopic fracture energy of glassy polymers from molecular simulations.

Rottler J, Barsky S, Robbins MO.

Phys Rev Lett. 2002 Sep 30;89(14):148304. Epub 2002 Sep 16.

PMID:
12366081
49.

MUC2 is a molecular marker for pseudomyxoma peritonei.

O'Connell JT, Hacker CM, Barsky SH.

Mod Pathol. 2002 Sep;15(9):958-72.

50.

Supplemental Content

Loading ...
Support Center